Genmab reports Daratumumab preliminary data in multiple myeloma
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity and is in clinical development for multiple myeloma. This ongoing Phase I/II dose escalation study comprised 122
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.